Home / Market News / $RVMD
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Oct 7, 2026, 5:07 PM UTC · Primary ticker $RVMD

Truist Securities analyst Gregory Renza has reiterated a 'Buy' rating for Revolution Medicines (RVMD) and slightly increased its price target from $239 to $240. This indicates continued analyst confidence in the company's prospects, though the minimal price target adjustment suggests no major new developments.

Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $239 to $240. This action signals ongoing analyst confidence in RVMD's future performance. While the 'Buy' rating is a positive signal, the very modest increase in the price target (just $1) suggests that this update is more of a reaffirmation of existing sentiment rather than a reaction to significant new information or a major re-evaluation of the company's fundamentals. For traders, this is a minor positive development, reinforcing the existing bullish outlook but unlikely to cause a substantial short-term price movement. Long-term investors might view this as continued validation of their investment thesis, but it doesn't introduce new catalysts.

$RVMD positive Analyst maintains Buy rating and slightly raises price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.